JORGE E CORTES to Bone Marrow Cells
This is a "connection" page, showing publications JORGE E CORTES has written about Bone Marrow Cells.
Connection Strength
0.299
-
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013 May; 88(5):350-4.
Score: 0.080
-
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 01; 102(5):1866-8.
Score: 0.040
-
Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002 Oct; 118(4):560-6.
Score: 0.039
-
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.
Score: 0.034
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.030
-
Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7.
Score: 0.017
-
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009 Jul; 192(1):18-23.
Score: 0.015
-
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009 Jun 18; 113(25):6315-21.
Score: 0.015
-
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801.
Score: 0.010
-
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9.
Score: 0.010
-
Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001 Nov 01; 19(21):4165-72.
Score: 0.009